418 related articles for article (PubMed ID: 17662520)
1. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
[TBL] [Abstract][Full Text] [Related]
2. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
[TBL] [Abstract][Full Text] [Related]
3. High-intensity focused ultrasound therapy for clinically localized prostate cancer.
Lee HM; Hong JH; Choi HY
Prostate Cancer Prostatic Dis; 2006; 9(4):439-43. PubMed ID: 16847468
[TBL] [Abstract][Full Text] [Related]
4. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience.
Blana A; Walter B; Rogenhofer S; Wieland WF
Urology; 2004 Feb; 63(2):297-300. PubMed ID: 14972475
[TBL] [Abstract][Full Text] [Related]
5. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.
Ganzer R; Robertson CN; Ward JF; Brown SC; Conti GN; Murat FJ; Pasticier G; Rebillard X; Thuroff S; Wieland WF; Blana A
BJU Int; 2011 Oct; 108(8 Pt 2):E196-201. PubMed ID: 21332907
[TBL] [Abstract][Full Text] [Related]
6. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
Uchida T; Illing RO; Cathcart PJ; Emberton M
BJU Int; 2006 Sep; 98(3):537-9. PubMed ID: 16925749
[TBL] [Abstract][Full Text] [Related]
7. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer.
Blana A; Murat FJ; Walter B; Thuroff S; Wieland WF; Chaussy C; Gelet A
Eur Urol; 2008 Jun; 53(6):1194-201. PubMed ID: 17997026
[TBL] [Abstract][Full Text] [Related]
8. High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up.
Challacombe BJ; Murphy DG; Zakri R; Cahill DJ
BJU Int; 2009 Jul; 104(2):200-4. PubMed ID: 19220245
[TBL] [Abstract][Full Text] [Related]
9. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
10. Control of prostate cancer by transrectal HIFU in 227 patients.
Poissonnier L; Chapelon JY; Rouvière O; Curiel L; Bouvier R; Martin X; Dubernard JM; Gelet A
Eur Urol; 2007 Feb; 51(2):381-7. PubMed ID: 16857310
[TBL] [Abstract][Full Text] [Related]
11. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.
Murat FJ; Poissonnier L; Rabilloud M; Belot A; Bouvier R; Rouviere O; Chapelon JY; Gelet A
Eur Urol; 2009 Mar; 55(3):640-7. PubMed ID: 18508188
[TBL] [Abstract][Full Text] [Related]
12. [Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10ng/ml].
Poissonnier L; Gelet A; Chapelon JY; Bouvier R; Rouviere O; Pangaud C; Lyonnet D; Dubernard JM
Prog Urol; 2003 Feb; 13(1):60-72. PubMed ID: 12703356
[TBL] [Abstract][Full Text] [Related]
13. Treatment of localized prostate cancer using high-intensity focused ultrasound.
Uchida T; Ohkusa H; Nagata Y; Hyodo T; Satoh T; Irie A
BJU Int; 2006 Jan; 97(1):56-61. PubMed ID: 16336329
[TBL] [Abstract][Full Text] [Related]
14. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.
Pfeiffer D; Berger J; Gross AJ
BJU Int; 2012 Dec; 110(11):1702-7. PubMed ID: 22928703
[TBL] [Abstract][Full Text] [Related]
15. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
16. Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer.
Inoue Y; Goto K; Hayashi T; Hayashi M
Int J Urol; 2011 May; 18(5):358-62. PubMed ID: 21449970
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
[TBL] [Abstract][Full Text] [Related]
18. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
19. [Locally recurrent prostatic adenocarcinoma after exclusive radiotherapy: results of high intensity focused ultrasound].
Poissonnier L; Murat FJ; Belot A; Bouvier R; Rabilloud M; Rouviere O; Chapelon JY; Gelet A
Prog Urol; 2008 Apr; 18(4):223-9. PubMed ID: 18501302
[TBL] [Abstract][Full Text] [Related]
20. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
